MY187848A - Anti-c5 antibodies and methods of use - Google Patents
Anti-c5 antibodies and methods of useInfo
- Publication number
- MY187848A MY187848A MYPI2018002581A MYPI2018002581A MY187848A MY 187848 A MY187848 A MY 187848A MY PI2018002581 A MYPI2018002581 A MY PI2018002581A MY PI2018002581 A MYPI2018002581 A MY PI2018002581A MY 187848 A MY187848 A MY 187848A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibody
- present
- provides
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the beta chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187848A true MY187848A (en) | 2021-10-26 |
Family
ID=59969459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018002581A MY187848A (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (4) | JP6202774B1 (en) |
| KR (2) | KR102226975B1 (en) |
| CN (3) | CN115960223A (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL263657B2 (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20190394A1 (en) |
| PH (1) | PH12018502354B1 (en) |
| SG (2) | SG10201800265UA (en) |
| TW (5) | TWI610941B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (en) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
| TWI654203B (en) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibodies with calcium-dependent antigen binding ability |
| EA201791366A1 (en) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION |
| MX2017005774A (en) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use. |
| CN114773469B (en) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | Antibodies comprising ion concentration-dependent antigen binding domains, variants of the FC region, IL-8-binding antibodies and uses thereof |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Antibodies against C5 and their uses |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Composition for preventing or treating IL-8 related diseases |
| MX2020003619A (en) * | 2017-10-04 | 2020-10-28 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis. |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| CN113038967B (en) | 2018-09-06 | 2026-07-14 | 宾夕法尼亚大学理事会 | Humanized anti-C5 antibodies and uses thereof |
| US20220204602A1 (en) * | 2019-04-24 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and their applications |
| JP7494413B2 (en) * | 2020-07-15 | 2024-06-04 | ビオシオン インコーポレイテッド | C5-binding antibody and its use |
| CN117042798A (en) * | 2020-12-25 | 2023-11-10 | 宾夕法尼亚大学理事会 | Humanized anti-C5 antibodies and Factor H fusion proteins and their uses |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP1410671B1 (en) | 2001-06-12 | 2011-01-12 | TELEFONAKTIEBOLAGET LM ERICSSON (publ) | Synchronisation in a umts terrestrial radio access network (utran) |
| MXPA04001301A (en) | 2001-08-17 | 2004-07-08 | Tanox Inc | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b. |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Polyethylene tube |
| WO2008113834A2 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| WO2008126921A1 (en) | 2007-04-11 | 2008-10-23 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| TWI468417B (en) * | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
| TW201920257A (en) * | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
| PY09026846A (en) * | 2008-08-05 | 2015-09-01 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES THAT TARGET THE C5 COMPLEMENT PROTEIN |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| NZ602220A (en) * | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for L / D optical conversion and optical splitting |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | Store point integrated management system and method |
| CN103534268B (en) * | 2010-10-20 | 2016-05-18 | 牛津生物疗法有限公司 | Antibody |
| NZ704771A (en) * | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| BR112015018438A2 (en) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | c5 antibody and method for preventing and treating complement-related diseases |
| JP6505079B2 (en) * | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Compositions and methods for increasing the serum half-life of a therapeutic that targets complement C5 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (en) * | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION |
| CN108401431B (en) * | 2015-12-18 | 2022-01-25 | 中外制药株式会社 | anti-C5 antibodies and methods of use |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active Active
- 2017-06-16 IL IL263657A patent/IL263657B2/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active Active
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en not_active Ceased
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 PH PH1/2018/502354A patent/PH12018502354B1/en unknown
- 2017-06-16 TW TW114113992A patent/TW202532438A/en unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
-
2024
- 2024-04-30 JP JP2024073302A patent/JP2024102181A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| ZA201703241B (en) | Anti-c5 antibodies and methods of use | |
| PH12018502354A1 (en) | Anti-c5 antibodies and methods of use | |
| MY188761A (en) | Method of reducing serum levels of fc-containing agents using fcrn antagonists | |
| PE20210107A1 (en) | ANTI-CD3 ANTIBODIES AND METHODS OF USE | |
| EA201591131A1 (en) | DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION | |
| PH12018501070A1 (en) | Anti-pcsk9 antibody and use thereof | |
| MX2019004940A (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody. | |
| MX2024006295A (en) | Dna monoclonal antibodies targeting influenza virus. | |
| ZA202104048B (en) | Anti-il-17a antibody and use thereof | |
| MX2025009846A (en) | COMPOSITIONS COMPRISING NUCLEIC ACID MOLECULES ENCODING SYNTHETIC ANTI-IL-6 AND ANTI-CD126 ANTIBODIES | |
| BR112017006203A2 (en) | isolated, caninized and monoclonal antibodies or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, isolated antigenic peptide, fusion protein, pharmaceutical composition, and method of enhancing the activity of an immune cell. | |
| EA201500546A1 (en) | MONOCLONAL ANTI-D ANTIBODIES WITH HIGH AFFINITY TO LOW AFFFIN Fcgamma RECEPTORS | |
| UA110226C2 (en) | Antibodies to cd38 |